Evidence map›Paper›PMID 41608299›Full record

ArticleFrontiers in neuroimaging2025

Neuroimaging evaluation of high dose methotrexate-induced neurotoxicity in pediatric and young adults: a PET/MRI study.

Zahra Shokri Varniab, Hyun Gi Kim, Ricarda von Krüchten, Yashas Ullas Lokesha, Kristina Elizabeth Hawk, Shashi Bhushan Singh, Tie Liang, Sarah Lu-Liang, Lucia Baratto, Michael Iv and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroimaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zahra Shokri VarniabMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Hyun Gi KimMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Ricarda von KrüchtenMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Yashas Ullas LokeshaMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Kristina Elizabeth HawkMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Shashi Bhushan SinghMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Tie LiangMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Sarah Lu-LiangMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Lucia BarattoMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.
Michael IvDivision of Neuroimaging and Neurointervention, Department of Radiology, Stanford University, Stanford, CA, United States.
Heike Elisabeth Daldrup-LinkMolecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, Stanford, CA, United States.

Funding

Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric PatientsR01CA269231 · NCI · STANFORD UNIVERSITY · PI Heike Elizabeth Daldrup-Link · 2022 to 2026
$3.5M
NCI NIH HHS R01 CA269231
6 · The paper itself

Abstract

Introduction: High-dose Methotrexate (HDMTX) can induce neurotoxicity, yet its impact on brain metabolism remains underexplored. This study aimed to assess short- and long-term brain metabolic changes post-HDMTX on 18F-FDG PET/MRI relative to baseline (pre-HDMTX) scans. Methods: In this IRB approved, retrospective study, we included 19 children and young adults (3 females and 16 males; age 17.9 ± 4.3 years), with lymphoma ( Results: In the short-term group, compared with baseline, both SUVmean (pre-HDMTX vs. post-HDMTX: 5.06 ± 1.62 vs. 6.31 ± 1.71, Discussion:

Indexed as

cancer survivorsmethotrexateneurotoxicitypediatric oncologyPET

Identifiers

PMID41608299
PMCPMC12834709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.